Postoperative Pain After Root Canal Obturation With Sealer Containing Prednisolone.

NCT ID: NCT04935736

Last Updated: 2022-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

243 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-30

Study Completion Date

2022-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study design is a multicentric randomized controlled clinical trial. 238 subjects (teeth) requiring a primary or a secondary root canal treatment will be enrolled in 2 groups (119 in each group).

The aim is to assess the effectiveness and utility of the ancillary drug substance, prednisolone acetate (1%) contained in CORTISOMOL SP (Zinc Oxide/Eugenol-type sealer) to help to decrease the possible postoperative painful reactions after root canal treatment. SEALITE REGULAR, which has a similar formulation except it is prednisolone acetate-free, is used as the comparator sealer.

Procedures of root canal treatment will be conventional and standardized for all investigational centers. The canals will be cleaned, shaped and then obturated using a Zinc oxide/Eugenol-type sealer (CORTISOMOL SP or SEALITE REGULAR) and gutta-percha.

Patients assess their pain for 7 days after permanent root canal obturation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Root Canal Obturation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Study subject (tooth) will be randomized in a 1:1 allocation ratio between the 2 treatment groups.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
the participant will be blind from the treatment

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CORTISOMOL SP

Zinc oxide/Eugenol-type sealer containing 1% Prednisolone Acetate. The sealer is used in combination with gutta percha points for the permanent obturation of root canals.

Group Type EXPERIMENTAL

root canal sealer : CORTISOMOL SP

Intervention Type DEVICE

The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.

SEALITE REGULAR

The Zinc oxide/Eugenol-type sealer is used in combination with gutta percha points for the permanent obturation of root canals.

Group Type ACTIVE_COMPARATOR

root canal sealer : SEALITE REGULAR

Intervention Type DEVICE

The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

root canal sealer : CORTISOMOL SP

The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.

Intervention Type DEVICE

root canal sealer : SEALITE REGULAR

The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, age \> 18 years old
* Patient requiring a primary or a secondary root canal treatment on a single or multi-rooted tooth.
* Informed consent signed
* Patient with social protection.

Exclusion Criteria

* Endodontic treatment on tooth with suspected root perforation, or immature tooth,
* Known allergy to corticosteroids, local anesthetics, or any component of the medical devices,
* Patient taking anti-pain or anti-inflammatory treatment regularly for another pathology,
* Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator,
* Participation in another intervnetional clinical trial or subject still within the exclusion period of a previous clinical trial,
* Vulnerable subjects referred to in articles L.1121-5 to 8 and L.1122-1-2 of the Public Health Code and article 66 of Regulation (EU) 2017/745 on medical devices are excluded from the investigation (such as known pregnancy or lactation, patients with legal protection).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Slb Pharma

OTHER

Sponsor Role collaborator

ACTEON Group

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hugues Colombel, DDS

Role: PRINCIPAL_INVESTIGATOR

Cabinet dentaire (Rennes)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cabinet dentaire

Lamballe, , France

Site Status

Cabinet dentaire

Liffré, , France

Site Status

Cabinet dentaire

Plédran, , France

Site Status

Cabinet dentaire

Pluguffan, , France

Site Status

Cabinet dentaire

Rennes, , France

Site Status

CHU Rennes - Centre de Soins Dentaires

Rennes, , France

Site Status

Cabinet dentaire

Saint-Brieuc, , France

Site Status

Cabinet dentaire

Saint-Coulomb, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A00525-36

Identifier Type: OTHER

Identifier Source: secondary_id

CORT-SP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.